La Trobe

Modification of lipid rafts by extracellular vesicles carrying HIV-1 protein Nef induces redistribution of amyloid precursor protein and Tau, causing neuronal dysfunction

journal contribution
posted on 2025-11-06, 04:07 authored by M Ditiatkovski, N Mukhamedova, D Dragoljevic, A Hoang, H Low, T Pushkarsky, Y Fu, I Carmichael, Andrew HillAndrew Hill, Andrew MurphyAndrew Murphy, M Bukrinsky, D Sviridov
HIV-associated neurocognitive disorders (HANDs) are a frequent outcome of HIV infection. Effective treatment of HIV infection has reduced the rate of progression and severity but not the overall prevalence of HANDs, suggesting ongoing pathological process even when viral replication is suppressed. In this study, we investigated how HIV-1 protein Nef secreted in extracellular vesicles (exNef) impairs neuronal functionality. ExNef were rapidly taken up by neural cells in vitro, reducing the abundance of ABC transporter A1 (ABCA1) and thus cholesterol efflux and increasing the abundance and modifying lipid rafts in neuronal plasma membranes. ExNef caused a redistribution of amyloid precursor protein (APP) and Tau to lipid rafts and increased the abundance of these proteins, as well as of Ab42. ExNef further potentiated phosphorylation of Tau and activation of inflammatory pathways. These changes were accompanied by neuronal functional impairment. Disruption of lipid rafts with cyclodextrin reversed the phenotype. Short-term treatment of C57BL/6 mice with either purified recombinant Nef or exNef similarly resulted in reduced abundance of ABCA1 and elevated abundance of APP in brain tissue. The abundance of ABCA1 in brain tissue of HIV-infected human subjects diagnosed with HAND was lower, and the abundance of lipid rafts was higher compared with HIV-negative individuals. Levels of APP and Tau in brain tissue correlated with the abundance of Nef. Thus, modification of neuronal cholesterol trafficking and of lipid rafts by Nef may contribute to early stages of neurodegeneration and pathogenesis in HAND.<p></p>

Funding

This publication was made possible by shared resources from NIH funding through the NIMH and NINDS by the following grants: Manhattan HIV Brain Bank (U24MH100931), Texas NeuroAIDS Research Center (U24MH100930) National Neurological AIDS Bank (U24MH100929), California NeuroAIDS Tissue Network (U24MH100928), Data Coordinating Center (U24MH100925).

The Manhattan HIV Brain Bank

National Institute of Mental Health

Find out more...

Texas NeuroAIDS Research Center

National Institute of Mental Health

Find out more...

NATIONAL NEUROLOGICAL AIDS BANK

National Institute of Mental Health

Find out more...

California NeuroAIDS Tissue Network

National Institute of Mental Health

Find out more...

NNTC Data Coordinating Center

National Institute of Mental Health

Find out more...

This work was supported by National Institutes of Health Grants HL131473 (to M. B. and D. S.) and NS102163 (to M. B.) and supported in part by funds from the Victorian Government's Operational Infrastructure Support Program (to D. S.) and Grant P30AI117970 from the District of Columbia Centre for AIDS Research, a National Institutes of Health-funded program (to M. B.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

History

Publication Date

2020-09-18

Journal

The Journal of Biological Chemistry

Volume

295

Issue

38

Pagination

16p. (p. 13377-13392)

Publisher

American Society for Biochemistry and Molecular Biology Inc.

ISSN

0021-9258

Rights Statement

© 2020 Ditiatkovski et al. Published under exclusive license by The American Society for Biochemistry and Molecular Biology, Inc. This is an Open Access article under the CC BY license: https://creativecommons.org/licenses/by/4.0